Bringing Innovation to Tissue Regeneration and Repair
Cardiovate has set out to solve one of the biggest problems with today's synthetic vascular grafts and stents. Over 60% graft failure occurs within 3 years. One in every 20 Americans over the age of 50 has a synthetic graft that puts them at a higher risk for heart attack and stroke.
Cardiovate is a medical technology company whose goal is to improve vascular repair outcomes by reducing failure rate and decreasing the total cost of care through development of next generation vascular regeneration technology. The company was formed in 2012 and is in early stages of product development currently funded by the UT Horizon Fund and founders
We are a fast paced upstart that will bring a significant improvement to the treatment of diseases such as Peripheral Artery Disease (PAD). We value patients and understand their struggles in dealing with the uncertainty of vascular diseases and we want to be seen as caring and providing better solutions for them.
News & Updates
San Antonio — An early stage San Antonio startup that aims to repair or replace clogged arteries with regenerated tissue has closed a small financing round from angel investors, The University of Texas Horizon Fund, and Targeted Technology, according to its CEO.
May 31, 2016 This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current
12500 Network Blvd Suite 310
San Antonio, Texas 77829
Research & Development
2500 Crosspark Rd. E-141 Coralville, IA 52241
© Copyright 2017 Cardiovate, Inc. All Rights Reserved.